FINWIRES · TerminalLIVE
FINWIRES

Top Cryptocurrencies Rise; Bitcoin Tops $73,000

By

Major digital assets rose Friday with Bitcoin (BTC-USD) topping $73,000.

The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell 0.2% in the past 24 hours. The Nasdaq 100 advanced 0.5%, the S&P 500 gained 0.2%, and the Dow Jones Industrial Average increased 0.7%.

Bitcoin rose 0.2% to $73,560, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume fell 14.7% to $35.14 billion.

Ethereum (ETH-USD), the second-largest digital asset by market value, rose 0.4% to $2,017.

XRP (XRP-USD) gained 0.8%, BNB (BNB-USD) rose 0.5%, and Solana (SOL-USD) added 0.3%. Dogecoin (DOGE-USD) climbed 0.9%, while Cardano (ADA-USD) dropped 0.3%.

The US 10-year Treasury yield stood at 4.451% at 3 p.m. ET Friday, down from 4.490% Thursday, while the five-year yield fell to 4.146% from 4.184%.

The total market value of the cryptocurrency industry advanced 0.3% in the past 24 hours to $2.48 trillion, with trading volume decreasing 13.7% to $90.38 billion.

Price: $73437.89, Change: $-87.85, Percent Change: -0.12%

Related Articles

Wire

Allied Gold Reports Regulatory Approvals for Acquisition by Zijin Gold

Allied Gold (AAUC) said late Friday Zijin Gold International has received approval under the Investment Canada Act for the acquisition of the company by Zijin.The company said the deal has also received clearance from the Regional Competition Authority of the Economic Community of West African States and the Competition and Consumer Commission of the Common Market for Eastern and Southern Africa.Completion of the transaction remains subject to receipt of outstanding regulatory approvals, it said.Price: $26.05, Change: $-1.13, Percent Change: -4.16%

$AAUC
Wire

Veracyte Says Prosigna Test Can Help High-Risk Breast Cancer Patients Avoid Chemotherapy

Veracyte (VCYT) said results from an independent Phase 3 trial show its Prosigna Breast Risk of Recurrence test can safely guide adjuvant chemotherapy decisions for patients with early-stage, ER-positive, HER2-negative breast cancer.The study, led by University College London, enrolled 4,429 patients and had a median follow-up of four years, Veracyte said Friday in a statement. Investigators reported that Prosigna provided Level 1A evidence, demonstrating the test can accurately predict chemotherapy benefit and support safe treatment de-escalation across high-risk groups.The results will be presented Saturday at the annual meeting of the American Society of Clinical Oncology.Price: $46.32, Change: $-1.67, Percent Change: -3.48%

$VCYT
Wire

Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint

Oculis Holding AG (OCS) said Thursday its Phase 3 DIAMOND-1 and DIAMOND-2 trials evaluating OCS-01 eye drops in patients with diabetic macular edema, a condition caused by fluid buildup in the retina due to diabetes, failed to meet primary endpoint of mean change in best corrected visual acuity, or BCVA.The drug did not demonstrate a statistically significant improvement in vision scores compared to vehicle, an inactive comparator, across both trial, the company said.The key secondary endpoint of the proportion of patients achieving a 15-letter or greater gain in BCVA was also not met in both trials.The drug was well tolerated with no unexpected adverse events, and the safety profile was consistent with previous trials, the company said.Based on the results, Oculis does not plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema at this time, and will redirect resources toward its two other registrational programs in optic neuropathies and dry eye disease.Price: $22.71, Change: $-6.95, Percent Change: -23.42%

$OCS